Alimera Sciences Inc (NASDAQ:ALIM) – Investment analysts at B. Riley boosted their FY2018 earnings per share estimates for Alimera Sciences in a research report issued to clients and investors on Wednesday, November 7th. B. Riley analyst A. D’silva now forecasts that the biopharmaceutical company will post earnings per share of ($0.22) for the year, up from their prior forecast of ($0.25). B. Riley also issued estimates for Alimera Sciences’ Q1 2019 earnings at ($0.05) EPS, Q2 2019 earnings at ($0.03) EPS, Q3 2019 earnings at ($0.02) EPS and Q4 2019 earnings at $0.00 EPS.
ALIM has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Alimera Sciences in a research note on Wednesday. Zacks Investment Research raised shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Thursday, August 2nd. Cowen reissued a “buy” rating and set a $3.00 price target on shares of Alimera Sciences in a research note on Wednesday, September 5th. Finally, TheStreet raised shares of Alimera Sciences from a “d-” rating to a “c-” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $2.44.
Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. The business had revenue of $11.14 million for the quarter, compared to the consensus estimate of $11.12 million.
Large investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in Alimera Sciences by 28.5% in the second quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 60,327 shares in the last quarter. Renaissance Technologies LLC increased its stake in Alimera Sciences by 20.8% in the second quarter. Renaissance Technologies LLC now owns 574,000 shares of the biopharmaceutical company’s stock valued at $562,000 after purchasing an additional 99,000 shares in the last quarter. Finally, Stonepine Capital Management LLC increased its stake in Alimera Sciences by 13.0% in the second quarter. Stonepine Capital Management LLC now owns 6,981,184 shares of the biopharmaceutical company’s stock valued at $6,830,000 after purchasing an additional 801,151 shares in the last quarter. 51.84% of the stock is owned by hedge funds and other institutional investors.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
See Also: What is a stock split?
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.